ADC Therapeutics SA Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ADC Therapeutics SA (ADCT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $1.45 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-27
- ADC Therapeutics SA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $1.45M, a 8.25% decline from fiscal 2023.
- ADC Therapeutics SA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $1.58M, a 76.07% decline from fiscal 2022.
- ADC Therapeutics SA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $6.58M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $1.45M 10-K · filed 2025-03-27 |
| 2023-12-31 | $1.58M 10-K · filed 2025-03-27 |
| 2022-12-31 | $6.58M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |